Carmell Therapeutics Corporation
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 48.77 | -100% | -10.75 | -100% |
| P/S |
|
0 | 33.76 | -100% |
|
|
| P/BV |
|
1.71 | 4.82 | -64.44% |
|
|
| P/FCF |
|
0 | 61 | -100% |
|
|
| Ev/Ebitda |
|
-8.18 | -22.15 | -63.07% |
|
|
| Ev/S |
|
11.26 | 22.56 | -50.11% |
|
|
| Ev/FCF |
|
-4.97 | 68.78 | -107.23% |
|
|
| E/P |
|
0 | 0.0178 | -100% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.98 | -100% | 0 | 0% |
| ROE |
|
-62.41 | 9.61 | -749.29% |
|
|
| ROA |
|
-24.15 | 0.3443 | -7115.72% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
-417.43 | -25.17 | 1558.43% |
|
|
| ROCE |
|
-21.08 | 15.35 | -237.33% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.4195 | -3.68 | -88.59% | -1.7 | -75.33% |
| Nеt Debt/Ebitda |
|
0.1524 | -3.44 | -104.43% |
|
|
| Debt/Ratio |
|
0.0334 | 0.1985 | -83.17% |
|
|
| Debt/Equity |
|
0 | 1.66 | -100% |
|
|
| Debt/Net Income |
|
-0.1383 | 10.32 | -101.34% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5468 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.2632 | -100% | ||
| DSI |
|
0 | 0.2193 | -100% |
|
|
| Average dividend growth |
|
0 | 0.4414 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4968 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5468 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
0/10
|
0 | -56.89 | -100% | ||
| Growth impulse Ebitda in 5 years |
|
37.63 | -54.68 | -168.82% | ||
| Growth impulse Net Income in 5 years |
|
137.62 | -58.33 | -335.93% | ||
| Growth impulse FCF in 5 years |
|
598.22 | -49.48 | -1309.01% | ||
| Growth impulse EPS in 5 years |
|
316.09 | -32.41 | -1075.29% |
IP Score
4.33/10
